Big Pharma is falling out of love with Britain
Life sciences should be a natural place to look for growth
Related reading
Britain is squeezing AstraZeneca too tight
NHS curbs on drug prices have alienated UK pharma companies and become self-defeating
UK biotech keeps selling itself to America
A shortage of late-stage capital pushes the biggest prizes into US hands
UK urges pharma companies to invest after reaching drug pricing deal with US
Accord will result in higher medicines spending in Britain in exchange for exemption from threatened Trump tariffs
Big pharma’s scramble over the patent cliff will be costly
Groups will need to buy mature biotechs to replace revenue lost to generic competitors
Eli Lilly not yet ready to unfreeze UK investments, says pharma boss
US drugmaker wants changes to types of drugs approved in Britain
Eli Lilly pushes for NHS drug price increases in return for its UK investment
US pharmaceutical group ‘optimistic’ about reaching deal with British government